[go: up one dir, main page]

TW200700066A - Compounds for inhibiting ksp kinesin activity - Google Patents

Compounds for inhibiting ksp kinesin activity

Info

Publication number
TW200700066A
TW200700066A TW095107698A TW95107698A TW200700066A TW 200700066 A TW200700066 A TW 200700066A TW 095107698 A TW095107698 A TW 095107698A TW 95107698 A TW95107698 A TW 95107698A TW 200700066 A TW200700066 A TW 200700066A
Authority
TW
Taiwan
Prior art keywords
compounds
ksp kinesin
kinesin activity
inhibiting ksp
inhibiting
Prior art date
Application number
TW095107698A
Other languages
English (en)
Inventor
Jayaram R Tagat
Timothy J Guzi
Marc Labroli
Cory Poker
Angela D Kerekes
Tao Yu
Hon-Chung Tsui
Neng-Yang Shih
Yushi Xiao
Sunil Paliwal
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of TW200700066A publication Critical patent/TW200700066A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095107698A 2005-03-09 2006-03-08 Compounds for inhibiting ksp kinesin activity TW200700066A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66013405P 2005-03-09 2005-03-09

Publications (1)

Publication Number Publication Date
TW200700066A true TW200700066A (en) 2007-01-01

Family

ID=36581831

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095107698A TW200700066A (en) 2005-03-09 2006-03-08 Compounds for inhibiting ksp kinesin activity

Country Status (9)

Country Link
US (1) US20060281778A1 (zh)
EP (1) EP1863571A1 (zh)
JP (1) JP2008533019A (zh)
CN (1) CN101171052A (zh)
AR (1) AR053158A1 (zh)
CA (1) CA2599901A1 (zh)
MX (1) MX2007010973A (zh)
TW (1) TW200700066A (zh)
WO (1) WO2006098962A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011647A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin ksp
WO2008079293A1 (en) * 2006-12-21 2008-07-03 Schering Corporation Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity
WO2009017701A2 (en) * 2007-07-31 2009-02-05 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
NZ583970A (en) 2007-10-11 2011-04-29 Univ California Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase
EP2220061B1 (en) 2007-10-19 2016-02-17 Merck Sharp & Dohme Corp. Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
US8609675B2 (en) 2009-07-02 2013-12-17 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds as novel mTOR inhibitors
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
IN2013MN02170A (zh) 2011-04-21 2015-06-12 Piramal Entpr Ltd
US8901142B2 (en) 2011-07-26 2014-12-02 Merck Sharp & Dohme Corp. Fused tricyclic compounds as mTOR inhibitors
SE1350211A1 (sv) * 2012-02-23 2013-08-24 Golden Biotechnology Corp Metoder och kompositioner för behandling av cancermetastaser
WO2014144836A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
WO2014144547A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
CN105777773B (zh) * 2015-12-25 2017-12-08 浙江师范大学 噻吩[2,3‑b]喹啉衍生物及其合成方法和应用
CN106967086B (zh) * 2017-03-20 2018-08-07 浙江师范大学 一种具有抗菌活性的喹啉并硫吡喃衍生物及其合成方法和应用
KR102604900B1 (ko) 2017-05-11 2023-11-21 브리스톨-마이어스 스큅 컴퍼니 Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581448A (en) * 1984-10-10 1986-04-08 Merrell Dow Pharmaceuticals Inc. Thienotriazines
JP3341288B2 (ja) * 1990-08-17 2002-11-05 三菱ウェルファーマ株式会社 ピリジン化合物および骨粗鬆症治療薬
AU3262593A (en) * 1992-01-11 1993-08-03 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
AU9384701A (en) * 2000-10-02 2002-04-15 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
RS50504A (sr) * 2001-11-08 2007-04-10 Elan Pharmaceuticals Inc., Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana
DE60222302T2 (de) * 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
DE10164139A1 (de) * 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP1534693A2 (en) * 2002-09-06 2005-06-01 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents

Also Published As

Publication number Publication date
US20060281778A1 (en) 2006-12-14
CN101171052A (zh) 2008-04-30
EP1863571A1 (en) 2007-12-12
MX2007010973A (es) 2007-09-19
AR053158A1 (es) 2007-04-25
WO2006098962A1 (en) 2006-09-21
JP2008533019A (ja) 2008-08-21
CA2599901A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
MXPA06012796A (es) Ciertas entidades quimicas, composiciones y metodos.
DE602004021472D1 (en) Pyrimiidinverbindungen
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
TW200744586A (en) Therapeutic compounds
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
SG170813A1 (en) New compounds
MY140767A (en) Compounds, methods and compositions
WO2007011760A3 (en) Inhibitors of mitotic kinesin
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2007106192A3 (en) Inhibitors of iap
MY140169A (en) Compounds, compositions, and methods
MX2010004312A (es) Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.
EA201170344A1 (ru) Азаиндольные ингибиторы iap
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
WO2007011759A3 (en) Inhibitors of mitotic kinesin
WO2007056469A3 (en) Certain chemical entities, compositions, and methods
MX2010007543A (es) Inhibidores de iap.
CR20220004A (es) Nuevos compuestos heterocíclicos
AU2003252025A8 (en) Compounds, compositions, and methods
WO2007120333A3 (en) Tetracyclic kinase inhibitors